Ezra Announces FDA Acceptance Of Filing Of New Drug Application For EZR-104 For The Treatment Of Hypertension And Heart Failure

LITTLE ROCK, Ark., Jan. 18, 2017 -- (Healthcare Sales & Marketing Network) -- Ezra Innovations, LLC (Ezra) today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for an investigational drug product, EZ... Biopharmaceuticals, Cardiology, FDA Ezra Innovations, valsartan, Rubireten
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news